These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 9582060)

  • 21. How Indian biotech is driving innovation.
    Nogrady B
    Nature; 2018 Dec; 564(7735):S53-S55. PubMed ID: 30542184
    [No Abstract]   [Full Text] [Related]  

  • 22. Biotech giant helps itself without swallowing Galapagos whole.
    Senior M
    Nat Biotechnol; 2019 Oct; 37(10):1104-1105. PubMed ID: 31578499
    [No Abstract]   [Full Text] [Related]  

  • 23. Stuck in the middle.
    Fuyuno I
    Nature; 2006 Jul; 442(7100):237. PubMed ID: 16855561
    [No Abstract]   [Full Text] [Related]  

  • 24. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 25. Trials and error.
    Jacobs T
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract]   [Full Text] [Related]  

  • 26. Sanofi Aventis grooms its ranks for biotech partnering.
    Moran N
    Nat Biotechnol; 2009 Jul; 27(7):581-2. PubMed ID: 19587645
    [No Abstract]   [Full Text] [Related]  

  • 27. First-quarter biotech job picture.
    Francisco M
    Nat Biotechnol; 2014 May; 32(5):497. PubMed ID: 24811521
    [No Abstract]   [Full Text] [Related]  

  • 28. Biotech battle royale. Two firms fight over billion-dollar drug.
    Sherrid P
    US News World Rep; 2000 Mar; 128(11):52. PubMed ID: 10848209
    [No Abstract]   [Full Text] [Related]  

  • 29. Genzyme deal set to alter biotech landscape.
    Ledford H
    Nature; 2011 Feb; 470(7335):449. PubMed ID: 21350458
    [No Abstract]   [Full Text] [Related]  

  • 30. Back on target.
    Webb S
    Nat Biotechnol; 2013 Mar; 31(3):191-3. PubMed ID: 23471062
    [No Abstract]   [Full Text] [Related]  

  • 31. Roche vows to keep Genentech culture.
    Hayden EC
    Nature; 2009 Mar; 458(7236):270. PubMed ID: 19295574
    [No Abstract]   [Full Text] [Related]  

  • 32. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 33. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 34. A very firm handshake: biotech's growing negotiating power.
    Thiel KA
    Nat Biotechnol; 2005 Oct; 23(10):1221-6. PubMed ID: 16211058
    [No Abstract]   [Full Text] [Related]  

  • 35. Biotech boot camp.
    Ledford H
    Nature; 2015 Mar; 519(7544):402-5. PubMed ID: 25810186
    [No Abstract]   [Full Text] [Related]  

  • 36. Bonsai biotech.
    Bains W
    Nat Biotechnol; 2009 Mar; 27(3):233. PubMed ID: 19270667
    [No Abstract]   [Full Text] [Related]  

  • 37. Life sciences venture capital in emerging markets.
    Chakma J; Sammut SM; Agrawal A
    Nat Biotechnol; 2013 Mar; 31(3):195-201. PubMed ID: 23471064
    [No Abstract]   [Full Text] [Related]  

  • 38. From the analyst's couch: The outlook for biotech exits.
    Grimaldi A
    Nat Biotechnol; 2014 Mar; 32(3):227-8. PubMed ID: 24727772
    [No Abstract]   [Full Text] [Related]  

  • 39. Genzyme-Sanofi buy out is second largest biotech deal ever.
    Ratner M
    Nat Biotechnol; 2011 Apr; 29(4):293-4. PubMed ID: 21478828
    [No Abstract]   [Full Text] [Related]  

  • 40. Biotech bonanza.
    Stipp D
    Fortune; 1999 Nov; 140(9):333-4. PubMed ID: 10623111
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.